Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
- Mr Hasegawa of Keizai Doyukai Welcomes Incoming Noda Administration
September 12, 2011
- Sales of Class 1 OTC Drugs Recovering Since January 2010: JSMI
September 12, 2011
- JGA to Prepare Transparency GLs
September 6, 2011
- Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
- JSGM Calls for Consideration of Generic Makers’ Cost Burden for Applications Based on Data in Public Domain
September 5, 2011
- Legal Prescription Rate Hits Record High 63.1% in FY2010: JPA
September 5, 2011
- 1st Meeting of Asia Cooperation Conference to Be Held Next March
September 5, 2011
- Keeping Premium for New Drug Development Will Stimulate Drug Development, R&D Spending: PhRMA
September 5, 2011
- Industry Objects to Proposals that Would Expand Range of Drugs Subject to Re-pricing
September 5, 2011
- FPMAJ Proposes Setting NHI Prices for All Generics at or Above Minimum Statutory Prices
September 5, 2011
- JPMA Publishes Guideline for Creating eCTDs(4th Ed.)
September 1, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…